Calliditas Therapeutics AB (publ) – NASDAQ:CALT
Calliditas Therapeutics AB (publ) stock price today
$40
+0.50
+1.27%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Calliditas Therapeutics AB (publ) stock price monthly change
+1.54%
month
Calliditas Therapeutics AB (publ) stock price quarterly change
+78.89%
quarter
Calliditas Therapeutics AB (publ) stock price yearly change
+117.03%
year
Calliditas Therapeutics AB (publ) key metrics
Market Cap | 1.08B |
Enterprise value | 149.46M |
P/E | -16.99 |
EV/Sales | 0.18 |
EV/EBITDA | -0.37 |
Price/Sales | 7.23 |
Price/Book | 7.57 |
PEG ratio | -0.96 |
EPS | -14.36 |
Revenue | 1.31B |
EBITDA | -409.15M |
Income | -524.81M |
Revenue Q/Q | 54.41% |
Revenue Y/Y | 38.80% |
Profit margin | -51.35% |
Oper. margin | -52.55% |
Gross margin | 98.11% |
EBIT margin | -52.55% |
EBITDA margin | -31.21% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCalliditas Therapeutics AB (publ) stock price history
Calliditas Therapeutics AB (publ) stock forecast
Calliditas Therapeutics AB (publ) financial statements
| Jun 2023 | 269.38M | -91.93M | -34.13% |
|---|---|---|---|
| Sep 2023 | 294.59M | -168.35M | -57.15% |
| Dec 2023 | 451.56M | -18.36M | -4.07% |
| Mar 2024 | 295.48M | -246.16M | -83.31% |
| Dec 2023 | 451.56M | -18.36M | -4.07% |
|---|---|---|---|
| Mar 2024 | 295.48M | -246.16M | -83.31% |
| Sep 2025 | 780.62M | 119.81M | 15.35% |
| Dec 2025 | 841.36M | 125.46M | 14.91% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-14 | -0.92 | -0.03 |
|---|---|---|
| 2023-02-23 | -0.00023 | -0.01 |
| Jun 2023 | 1709147000 | 1.20B | 70.49% |
|---|---|---|---|
| Sep 2023 | 1611891000 | 1.25B | 78.14% |
| Dec 2023 | 1900549000 | 1.56B | 82.38% |
| Mar 2024 | 1688295000 | 1.56B | 92.88% |
| Jun 2023 | -163.03M | -1.06M | -3.01M |
|---|---|---|---|
| Sep 2023 | -62.52M | -7.41M | -2.88M |
| Dec 2023 | 22.84M | -2.35M | 208.52M |
| Mar 2024 | -198.20M | -3.85M | -5.46M |
Calliditas Therapeutics AB (publ) alternative data
| Aug 2023 | 181 |
|---|---|
| Sep 2023 | 169 |
| Oct 2023 | 169 |
| Nov 2023 | 169 |
| Dec 2023 | 174 |
| Jan 2024 | 174 |
| Feb 2024 | 174 |
| Mar 2024 | 192 |
| Apr 2024 | 192 |
| May 2024 | 192 |
| Jun 2024 | 217 |
| Jul 2024 | 219 |
Calliditas Therapeutics AB (publ) other data
0.01%
-1.78%
of CALT is owned by hedge funds
6.64K
-946.50K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 23 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q1 2021 18 May 2021 | Q1 2021 Earnings Call Transcript |
Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments
Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (Maintaining Buy)
Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point
Calliditas: Riding The Setanaxib Wave And Betting On Tarpeyo's Triumph
Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company
Omeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023
Calliditas: A Trailblazing Triumph In IgAN Treatment
Calliditas Therapeutics: Good Long-Term Data Could Boost Tarpeyo Sales
Calliditas: Underfollowed Swedish Biotech Focusing On Rare Kidney Disease
-
What's the price of Calliditas Therapeutics AB (publ) stock today?
One share of Calliditas Therapeutics AB (publ) stock can currently be purchased for approximately $40.
-
When is Calliditas Therapeutics AB (publ)'s next earnings date?
Unfortunately, Calliditas Therapeutics AB (publ)'s (CALT) next earnings date is currently unknown.
-
Does Calliditas Therapeutics AB (publ) pay dividends?
No, Calliditas Therapeutics AB (publ) does not pay dividends.
-
How much money does Calliditas Therapeutics AB (publ) make?
Calliditas Therapeutics AB (publ) has a market capitalization of 1.08B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 50.32% to 1.21B US dollars. Calliditas Therapeutics AB (publ) made a loss 466.19M US dollars in net income (profit) last year or -$0.01 on an earnings per share basis.
-
What is Calliditas Therapeutics AB (publ)'s stock symbol?
Calliditas Therapeutics AB (publ) is traded on the NASDAQ under the ticker symbol "CALT".
-
What is Calliditas Therapeutics AB (publ)'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Calliditas Therapeutics AB (publ)?
Shares of Calliditas Therapeutics AB (publ) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Calliditas Therapeutics AB (publ) have?
As Jul 2024, Calliditas Therapeutics AB (publ) employs 219 workers, which is 1% more then previous month and 14% more then previous quarter.
-
When Calliditas Therapeutics AB (publ) went public?
Calliditas Therapeutics AB (publ) is publicly traded company for more then 5 years since IPO on 5 Jun 2020.
-
What is Calliditas Therapeutics AB (publ)'s official website?
The official website for Calliditas Therapeutics AB (publ) is calliditas.se.
-
How can i contact Calliditas Therapeutics AB (publ)?
Calliditas Therapeutics AB (publ) can be reached via phone at +46 8 411 30 05.
Calliditas Therapeutics AB (publ) company profile:
Calliditas Therapeutics AB (publ)
calliditas.seExchange:
NASDAQ
Full time employees:
222
Industry:
Biotechnology
Sector:
Healthcare
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Kungsbron 1, D5
Stockholm, 111 22
Stockholm, 111 22
CIK: 0001795579
ISIN: US13124Q1067
CUSIP: 13124Q106
